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Abstract
Hypothyroidism is a very common condition and can be seen throughout the lifespan.
The effects on heart function include decreased contractility, increased peripheral vascular
resistance, increased diastolic blood pressure and irregular heart rhythms (ATA, 2020). The case
study in this report shows typical symptoms of hypothyroidism and proper treatment. The
findings collected in this study suggest it beneficial to treat symptomatic subclinical
hypothyroidism with added benefits of preserving cardiac dysfunction. But more studies need to
be conducted to ensure the efficacy of treating both asymptomatic and symptomatic subclinical
hypothyroidism. Having a better understanding of thyroid function and its impact on the heart
will allow healthcare providers to make better clinical decisions when treating hypothyroidism
and subsequent cardiac dysfunction. In this study, the focus is on the effects of hypothyroidism
and how it plays a role in cardiac function.
Background
Hypothyroidism is an underactive thyroid gland. Hypothyroidism means that the thyroid
gland doesn’t make enough thyroid hormone to keep the body running normally. Common
causes are autoimmune disease, such as Hashimoto’s thyroiditis, surgical removal of the thyroid,
and radiation treatment (ATA, 2020). When thyroid hormone levels are too low, the body’s cells
are deprived of circulating free T3 and T4 and the body’s metabolic processes start slowing
down. Symptoms of hypothyroidism include feeling colder, malaise or tire more easily, dry skin,
forgetfulness, depression, and constipation (ATA, 2020). Because the symptoms of
hypothyroidism are so variable and nonspecific, the only way to know for sure is with a blood
test for thyroid stimulating hormone (TSH). Normal range should be between 0.4-4.0 (ATA,
2020).
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Hypothyroidism may not cause noticeable symptoms in the early stages. Over time,
untreated hypothyroidism can cause a number of health problems, such as obesity, joint pain,
infertility and heart disease. Accurate thyroid function tests are available to diagnose
hypothyroidism. The most common cause of hypothyroidism is an autoimmune disorder known
as Hashimoto's thyroiditis. Autoimmune disorders occur when your immune system produces
antibodies that attack your own tissues. Sometimes this process involves your thyroid gland. The
trace mineral iodine found primarily in seafood, seaweed, plants grown in iodine-rich soil and
iodized salt is essential for the production of thyroid hormones. Too little iodine can lead to
hypothyroidism, and too much iodine can worsen hypothyroidism in people who already have
the condition. In some parts of the world, iodine deficiency is common, but the addition of iodine
to table salt has virtually eliminated this problem in the United States (Mayo Clinic, 2019).
Hypothyroidism can be further divided into “overt” and “subclinical” hypothyroidism.
Hypothyroidism is diagnosed when low levels of the thyroid hormones result in elevated levels
of TSH (Udovcic et al, 2017). Subclinical hypothyroidism is defined as a state with high TSH
with normal blood levels of T4 and T3 (Udovcic et al, 2017). Subclinical hypothyroidism (SHT)
is diagnosed when the above listed is present along with being symptomatic (Udovcic et al,
2017). Although, up to 60% of patients with subclinical hypothyroidism can return to
euthyroidism over 5 years, again based on TSH levels and antibody status. (Udovcic et al. 2017).
The major effects of thyroid hormones on the heart are mediated by triiodothyronine
(T3). Indeed, T3 generally increases the force and speed of systolic contraction and the speed of
diastolic relaxation. In addition, T3 decreases vascular resistance, including coronary vascular
tone, and increases coronary arteriolar angiogenesis (Grais & Sowers, 2014). These multiple
thyroid hormone effects are largely mediated by the action of nuclear-based thyroid hormone
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receptors (TR), specifically the TRα and -β. TRα is the predominant TR isoform in the heart, and
it is the predominant subtype through which T3 binds to nuclear TRs and signals in
cardiomyocytes (Grais & Sowers, 2014).
Thyroid hormone plays a large role in cardiovascular function. Thyroid hormones can promote
both physiological and pathological myocardial hypertrophy. In this regard, cardiac hypertrophy,
in its initial phases, presents a physiological process that includes increased adenosine
triphosphatase (ATP) and gene expression of the sarcoplasmic reticulum Ca 2+ (SERCa 2+) and
decreased expression of MHCβ. T3-activated TR cardiac effects also include the regulation of
cation transport (Grais & Sowers, 2014). Regulation of intracellular Ca 2+ ([Ca 2+] I) is
important for both normal systolic and diastolic function. For example, T3 promotes increases in
SERCa 2+ ATPase and the ryanodine channel, and decreases phosphorylation/activation of
phospholamban, which functions to inhibit the SERCa 2+ pump.
Diastolic function of the heart is substantially influenced by the thyroid status. The speed
of diastolic relaxation in the heart is markedly influenced by lowering of the [Ca 2+] I levels. In
cardiomyocytes, most [Ca 2+] I lowering is achieved by pumping [Ca 2+] I into the sarcoplasmic
reticulum by the SERCa 2+ pump. Experimental results in animal models of hypothyroidism
indicate that the level and activity of the SERCa 2+ pump is markedly decreased and that of
inhibitory phospholamban increased (Grais & Sowers, 2014). These SERCa 2+ and
phospholamban changes can be linked to a decrease in the rate of diastolic relaxation. Finally,
the β 1 adrenergic and the TRα receptors are positively and negatively regulated by T3,
respectively, which promotes optimal modulation of T3-activated TR inotropic and chronotropic
cardiac effects (Grais & Sowers, 2014).
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Thyroid hormones exert effects on the vasculature that generally lead to reduced vascular
tone and maintenance of normal arteriolar remodeling. It has been known for two decades that
T3 exerts direct effects on vascular smooth muscle cells to promote relaxation (Grais & Sowers,
2014). Several mechanisms for this T3-mediated vascular relaxation have been reported. For
example, it has been demonstrated that T3 dose-dependently reduces expression of the
angiotensin (Ang) II type 1 receptor and reduces the increased [Ca 2+] I and contractile response
to Ang II (Grais & Sowers, 2014). Further, T3 stimulates nitric oxide (NO) production via
activation of the phosphoinositol 3-kinase/protein kinase B-mediated endothelial NO synthase
signaling pathway (Grais & Sowers, 2014). The resulting increase in bioavailable NO is
associated with decreased myosin light chain phosphorylation in response to Ang II and
phenylephrine (Grais & Sowers, 2014). Collectively, these data suggest that T3 reduces vascular
smooth muscle cell contraction by decreasing [Ca 2+] I as well as Ca 2+ sensitization (Grais &
Sowers, 2014). Grais and Sowers (2014) have shown that T3 also promotes angiogenesis and
increases the density of small arterioles, including coronary arterioles. This T3-activated TR
effect on coronary arterioles may be especially important following myocardial ischemia and in
the process of myocardial ischemic reconditioning (Grais & Sowers, 2014).
Case Report
Subjective: Jane Doe is a 42-year-old female that presents to the clinic with complaints of
increased fatigue, weight gain, hair loss and occasional slowed heart rate. At this time, she
noticed she was feeling more tired than usual, unable to do the tasks she has come accustomed to
without being fatigued. She complains of unusual weight gain without a change in diet or
activity. She also noticed more hair falling out in the shower. She denies shortness of breath,
nausea/vomiting, abdominal pain, changes in hearing or vision, headaches, muscle aches or
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changes in bladder or bowel habits. Patient is not currently on any medications, occasionally
takes multivitamin, no iodine supplements. Family history of hyperthyroidism in mother and
heart disease in father, died of “heart attack” at age 65.
Objective: labs: TSH: 7.5

T3: wnl

T4: 3 ug/dl

CBC: wnl

BMP: wnl

Hcg: negative
Vitals: HR 59, BP 135/89, temp 98.7, RR 16, weight 165 lb, height 5’8”
12-lead ECG: normal sinus rhythm with bradycardia
Assessment: no thyroid nodules palpated, no cervical or tonsillar adenopathy, grade 2
systolic murmur heard over left and right sternal border, S1 and S2 heard. Lung sounds normal,
no rhales, wheezes or rhonchi. Nails and hair are brittle, no suspicious moles or lesions. Denies
any influenza like symptoms, no changes in hearing or vision, denies headaches, denies syncopal
episodes.
Plan: given her elevated TSH and decreased T4 it is likely she has overt hypothyroidism.
Patient was started on Levothyroxine 25 mcg oral once daily. She will follow up in 6 weeks. We
also discussed fasting at next visit as we will be checking a lipid panel and blood sugar. Given
that she is bradycardic, hypertensive and has a family history of heart disease we will follow up
with further cardiac testing.
Literature Review
This review will focus on the early recognition and need for treatment in subclinical
hypothyroidism as it relates to preserving and correcting suboptimal heart function. The main
areas of focus include: pharmacologic therapy, treating subclinical hypothyroidism in patients to
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prevent or improve cardiac dysfunction, monitoring and duration of treatment and treating
subclinical hypothyroidism as a clinical diagnosis.
Pharmacologic Therapy
Hypothyroidism is typically treated with levothyroxine in order to attain a euthyroid
state. Doses typically start at 25mcg oral levothyroxine daily. Grais and Sowers (2014) discussed
the slow progression and initial starting dose of levothyroxine as low as 12.5mcg oral daily for
those with known CAD and decreased heart function. It’s also important to determine if
hypothyroidism is caused by autoimmune disorders as this will affect treatment plan for dosing
and monitoring.
In a study performed by Jabbar et al (2015) the target TSH was between 0.4 to 2.5 mU/L.
Levothyroxine dosing was consistent in both studies with small doses starting at 25mcg daily
with the dose being increased every four weeks. Increases were made at 25 mcg increments
every four weeks until the serum TSH is within the target range. Safety measures (ECG,
symptoms of heart failure, and pulse oximetry) were assessed at visits two and six.
Treating Subclinical Hypothyroidism to Prevent or Improve Cardiac Dysfunction
Thyroid dysfunction is compensated for by the greater stimulation of TSH from the
anterior pituitary gland (Grais & Sowers, 2014). Despite normal levels of thyroid
hormone(T3,T4), SHT patients are at somewhat increased risk of atherosclerosis (Grais &
Sowers, 2014). The clinical decision about starting thyroid supplement therapy will be
influenced by the age of the patient, the cause of the hypothyroidism, and the presence of other
atherosclerotic risk factors including hypertension and dyslipidemia (Grais & Sowers, 2014).
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These risk factors for atherosclerosis require appropriate medical management along with
thyroid supplementation (Grais & Sowers, 2014).
Endothelial dysfunction is a known early progenitor of hypertension and atherosclerosis.
There is evidence of decreased nitric oxide (NO)-mediated vascular relaxation in patients with
subclinical hypothyroidism, as demonstrated by abnormal flow-mediated vasodilatation (Grais &
Sowers, 2014). Flow-mediated vasodilatation depends on the presence of adequate bioavailable
NO in the endothelium. Evaluation of endothelial-mediated vascular relaxation has revealed
reduced flow-mediated vasodilatation in individuals with subclinical hypothyroidism (Grais &
Sowers, 2014). Baseline and flow-mediated (NO-dependent) vasodilatation values were
significantly higher in individuals with subclinical hypothyroidism after treatment with Lthyroxin. Grais and Sowers (2014) support the notion that thyroid replacement therapy is
beneficial in patients with subclinical hypothyroidism. Left and right ventricular systolic and
diastolic dysfunction also have been described in subclinical hypothyroidism, and there is
evidence for improvement in ventricular function with thyroid replacement therapy (Grais &
Sowers, 2014).
Subclinical hypothyroidism is associated with an increased risk of coronary heart disease
events and mortality with elevated TSH levels, especially in those with values greater than 10
mIU/L. Udovcic et al (2017) suggested an increased risk of coronary heart disease,
cardiovascular mortality and an increased risk of cardiovascular disease in younger individuals
with the cut-off age varying from 50 to 70 years. Treatment with levothyroxine in those with
overt thyroid dysfunction has been shown to improve LDL cholesterol, total cholesterol,
triglycerides, hypertension, diastolic dysfunction, heart rate, and heart rate variability in exercise
and to delay progression of atherosclerosis (Udovcic et al, 2017). Patients with cardiomyopathies
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may demonstrate improved cardiac contractility and stroke volume with levothyroxine treatment
(Udovcic et al, 2017). One of the main concerns with starting levothyroxine replacement is the
precipitation of myocardial ischemia or arrhythmias, which, although rare, are known to occur
(Udovcic et al, 2017).
In subclinical hypothyroidism patients, increased left ventricular (LV) myocardial proton
spin-lattice relaxation time (T1) suggest myocardial injury might occur even when serum FT3
were normal (Liu et al, 2018). SHT could alter collagen, myocardial fiber orientation, tissue
water content, and capillary blood flow distribution, however, the mechanism of the elevation of
LV myocardial T1 remains unclear. Thyroid hormone correlated with LV myocardial T1,
indicating that decreased serum thyroid hormone might associate with the myocardial diffused
abnormality and T1 value can be regarded as non-invasive surrogate of mild myocardial injury
induced by HT (Liu et al, 2018).
The alterations found in myocardial function, metabolic profile, and vascular function
suggest that patients with untreated subclinical hypothyroidism may be at increased risk of
adverse cardiovascular outcomes. However, individual-patient meta-analysis performed by the
Thyroid Studies Collaboration, a consortium of cohort studies with data from more than 75,000
participants, did not demonstrate an association of subclinical hypothyroidism with increased
risk of atrial fibrillation, heart failure, stroke, coronary heart disease events, mortality from
coronary heart disease, or overall mortality compared with euthyroid individuals (JAMA, 2019).
In contrast, when data were analyzed, stratified by degree of thyrotropin elevation, thyrotropin
levels of 10 mU/L or higher were associated with increased risk of heart failure, coronary heart
disease events, and mortality from coronary heart disease compared with normal thyrotropin
values (JAMA, 2019). In addition, thyrotropin values of 7.0 to 9.9 mU/L were associated with
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increased risk of fatal stroke and mortality from coronary heart disease. The findings from the
Journal of American Medical Association suggest that the severity of subclinical hypothyroidism
is associated with greater cardiovascular risk.
The Journal of American Medical association suggest that treatment might be indicated for
patients with subclinical hypothyroidism and serum thyrotropin levels of 10 mU/L or higher.
Also, for young and middle-aged individuals with subclinical hypothyroidism and symptoms
consistent with mild hypothyroidism, thyrotropin values of 7.0 to 9.9 mU/L (JAMA, 2019).
The Cardiovascular Health Study showed that SHT participants who were treated with
levothyroxine had a 72% reduction in heart failure events (Jabbar et al, 2015). Thus, even mild
hypothyroidism following acute myocardial infarction could be an important marker for poor
outcome. Therefore, thyroxine in acute myocardial infarction needs further investigation and
trials to prove its efficacy (Jabbar et al, 2015).
Monitoring and Duration of Treatment
The study done by Jabbar et al (2015) completed a 52-week study that kept their target
TSH between 0.4 to 2.5 post AMI. After the study was complete, they sent data and
recommendations to the patient’s PCP in which it was the primary’s discretion on whether to
continue to treat their SHT. It was recommended to recheck the patients TSH after 6-weeks.
Because increased age is a risk factor for hypothyroidism, hypertension and cardiovascular
disease, its important to monitor TSH levels as it can be easily performed in the clinic setting
(Udovcic et al, 2017).
The JAMA, Udovcic, Jabbar, Liu, Grias and Sowers, Stott all discuss the effects of
hypothyroidism on the heart. All of which show data that supports the added cardiovascular
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benefit of being euthyroid. There needs to be more studies conducted for treating SHT post AMI
to really support the evidence. At this point there is no recommended time that patients with
subclinical hypothyroidism should be on levothyroxine post AMI. The goal of preserving heart
function which is to reduce workload on the heart by decreasing vascular resistance and
increasing cardiac contractility. Being euthyroid will only be beneficial in reducing mortality as
it relates to heart function (Udovcic et al, 2017).
Treating Subclinical Hypothyroidism
Overtreatment of SCH can cause complications and symptoms of thyrotoxicosis have
been reported. Nervousness and anxiety were reported and some subjects “felt worse” following
treatment in a placebo-controlled study (Stott et al, 2017). Tachyarrhythmias and angina pectoris
were also reported. Low bone mass and fractures are also potential complications of treatment.
Stott et al (2017) demonstrated the safety of thyroxine for the treatment of SCH, as no
participants reported adverse effects, required dose reduction or withdrew from the studies (Stott
et al, 2017).
For now, the treatment decision needs to be individualized. Treatment may be considered
if: (a) symptoms are present; (b) there is a goiter; (c) there is risk of progression to OH; (d) there
are risks of heart disease, particularly in patients younger than 70 years of age; or TSH levels
exceed 10 mIU/L. Furthermore, SHT should be identified accurately (if possible) and treated
adequately in pregnant women, lactating mothers, neonates and children. This is because
unidentified and untreated SCH in these populations may lead to dire consequences (Stott et al,
2017).
Discussion
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The evidence is still unclear as to whether subclinical hypothyroidism should be treated.
The evidence is supportive of treating hypothyroidism as it relates to cardiac dysfunction. In the
clinic setting it will be up to the primary care provider whether or not to treat SHT with hormone
replacement. The information gathered from the American Thyroid Association, seven of the
nine articles in the literature review suggest hormone replacement is beneficial to treat
subclinical hypothyroidism as it relates to cardiac dysfunction. In the other two studies there was
not enough data that suggested definitive treatment of subclinical hypothyroidism for each
individual. The Journal of the American Medical Association recommended that treatment of
subclinical hypothyroidism be patient based along with being symptomatic and under the age of
65, unless without evidence of CAD or recent MI (JAMA, 2019).
Learning Points
•

Subclinical hypothyroidism will likely develop into overt hypothyroidism. Proper
monitoring and subsequent thyroid replacement therapy should be implemented.

•

The evidence is clear that thyroid hormone effects lipid levels. Treating those with
symptomatic SHT and familial hyperlipidemia will help reduce mortality as it relates to
cardiac dysfunction.

•

Those 65 and older in need of thyroid hormone replacement should initiate levothyroxine
at a low does and progress slowly. Especially with a history of CAD and MI.

•

For those <65 years old with subclinical hypothyroidism and are symptomatic (weight
gain, malaise, hypertension) would benefit from hormone replacement with
levothyroxine.

•

In the primary care setting for patients post AMI it would be prudent to check TSH levels
4-6 weeks to screen for overt and subclinical hypothyroidism.
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